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Abstract
Background Weight loss (WL) has long been recognized as an important factor associated with reduced quality of life (QoL)
and reduced survival in patients with cancer. The body mass index (BMI)-adjusted weight loss grading system (WLGS) has been
shown to be associated with reduced survival. However, its impact on QoL has not been established. The aim of this study was
to assess the relationship between this WLGS and QoL in patients with advanced cancer.
Methods A biobank analysis was undertaken of adult patients with advanced cancer. Data collected included patient demo-
graphics, Eastern Cooperative Oncology Group performance status, and anthropometric parameters (BMI and %WL). Patients
were categorized according to the BMI-adjusted WLGS into one of ﬁve distinct WL grades (grades 0–4). QoL was collected
using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. The Kruskal–
Wallis test and multivariate logistic regression analyses were used to assess the relationship between the WLGS and QoL
scores. Overall survival was assessed using Kaplan–Meier curve and Cox proportional hazard models.
Results A total of 1027 patients were assessed (51% male, median age: 66 years). Gastrointestinal cancer was most preva-
lent (40%), and 87% of patients had metastatic disease. Half (58%) of patients had a WL grade of 0–1, while 12%, 20%, and
10% had WL grades of 2, 3, and 4, respectively. Increasing WL grades were signiﬁcantly associated with poorer QoL functioning
and symptoms scales (all P < 0.05). Physical, role, and emotional functioning decreased by a median of >20 points between
WL grade 0 and WL grade 4, while appetite loss, pain, dyspnoea, and fatigue increased by a median score >20 points, indic-
ative of a large clinical signiﬁcant difference. Increasing WL grades were associated with deteriorating QoL summary score. WL
grades 2, 3, and 4 were independently associated with a QoL summary score below the median (<77.7) [odds ratio (OR) 1.69,
P = 0.034; OR 2.06, P = 0.001; OR 4.29, P < 0.001, respectively]. WL grades 3 and 4 were independently associated with re-
duced overall survival [hazard ratio 1.54 (95% conﬁdence interval: 1.22–1.93), P < 0.001 and hazard ratio 1.87 (95% conﬁ-
dence interval: 1.42–2.45), P < 0.001, respectively].
Conclusions Our ﬁndings support that the WLGS is useful in identifying patients at risk of poor QoL that deteriorates with
increasing WL grades. WL grade 4 is independently associated with a particularly worse prognosis and increased symptom bur-
den. Identiﬁcation and early referral to palliative care services may beneﬁt these patients.
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Introduction
Weight loss (WL) has long been recognized as an important
and prognostic clinical feature in patients with cancer. Invol-
untary WL is estimated to affect between 30% and 70% of pa-
tients and has been associated with reduced quality of life
(QoL) and physical function, poorer tolerance to anti-cancer
therapy, and shortened survival in patients with cancer.1–4
WL is a cardinal feature of cancer cachexia, a condition charac-
terized by the loss of muscle with or without the loss of fat
mass, leading to progressive functional impairment.5 How-
ever, current deﬁnitions and thresholds for deﬁning clinically
important WL are unclear, particularly in the face of a global
obesity epidemic. The use of minimum reported degrees of
WL (e.g.>5% or 10% over 3–6months) is arbitrary and heter-
ogenous and not based on speciﬁc values that relate to ad-
verse clinical outcome. It has been suggested that the
severity of WL should be evaluated based on the rate of WL
in the context of initial body reserves and that thresholds for
clinically important WL should relate optimally to meaningful
patient-centred outcomes, such as decreased survival.5
In 2015, Martin et al. aimed to redeﬁne clinically important
WL that was prognostic of outcome in a large dataset of >10
000 cancer patients across Europe and Canada.6 This dataset
was used to develop and validate a new grading system for
cancer-associated WL based on risk stratiﬁcation with survival
as the outcome. The authors used a 5 × 5matrix analysis of 25
possible combinations of %WL and body mass index (BMI) and
combining groups with similar hazard ratios (HRs). From this,
they devised the BMI-adjusted weight loss grading system
(WLGS) that composed of ﬁve distinct WL grades with signiﬁ-
cantly different survival rates. Median survival was longest
for WL grade 0 (20.9 months) and shortest for WL grade 4
(4.3 months). Importantly, these observations were indepen-
dent of tumour site, stage, and performance status (PS).6
TheWLGSmarked a step forward in redeﬁning clinically impor-
tant WL and has been included in the current international
clinical practice guidelines for nutrition and cancer.7
Since then, the WLGS has had its prognostic validity con-
ﬁrmed in a cohort of oncology patients.8 Further, the WLGS
was also associated with cachexia-related domains such as re-
duced dietary intake, anorexia, reduced PS, and increased fa-
tigue, suggesting that the WLGS may be useful in cachexia
classiﬁcation.8 However, the relationship between the WLGS
and QoL is unclear. The relationship between WL in isolation
and reduced QoL has long been recognized, and this was con-
ﬁrmed in a systematic review in 2013, whereby a negative re-
lationship between WL and QoL was reported in 23 of the 27
studies.9 However, the WLGS that incorporates BMI in addi-
tion to WL and is the most robust prognostic framework
using these domains published to date may also relate to
QoL; however, this has yet to be elucidated.
Therefore, the aim of the present study was to ﬁrst assess
the prognostic validity of the WLGS in an external cohort of
patients with advanced cancer and, second, examine the rela-
tionship between the WLGS and QoL in patients with ad-
vanced cancer and assess if increasing WL grades are
capable of identifying patients at risk of impaired QoL.
Patients and methods
A biobank analysis of patients with cancer was performed.
These data were collected prospectively from 18 centres (11
cancer centres and 7 specialist palliative care units) across
the UK and Ireland10,11 between 2011 and 2016. Individual
centres were opened at staggered time points, and a conve-
nience sampling approach was adopted. For the primary data
collection, both oncology inpatients and outpatients were
recruited. Eligible patients were >18 years of age and have
advanced cancer [deﬁned as metastatic cancer (histological,
cytological, or radiological evidence), locally advanced or re-
ceiving anti-cancer therapy with palliative intent]. Willing par-
ticipants provided written informed consent. Exclusion criteria
included patients that were under the age of 18 years and
those that were unwilling or unable to participate due to cog-
nitive impairment. All participants provided written informed
consent, ethical approval was given (UK—12/SS/0181 and
EMC 4(g) 2015 Ireland), and the studies were conducted ac-
cording to good clinical practice and applicable laws.
Patient information recorded
On assessment, patient’s weight, height, and BMI were re-
corded [weight (kg)/height (m2)]. Body weight was measured
to within 0.1 kg, using a digital scale. Height was measured to
within 0.5 cm using a wall-mounted stadiometer. Patient-
reported history of WL in the preceding 3 months was
assessed and recorded in a study-speciﬁc questionnaire and
when possible veriﬁed from patient’s medical records. From
this, percentage WL (%WL) was calculated [weight lost (kg)/
current weight (kg) × 100]. WL grade was assessed and given
a score of 0–4 by combining WL and current BMI according to
Martin et al. (Table 1).6 Clinical and pathological data were
collected and included information on patient demographics
Table 1 Grade of weight loss (0–4) based on percentage weight loss and
current body mass index6
Body mass index (kg/m2)
Weight loss (%) ≥28 25–27.9 22–24.9 20–21.9 <20
±2.4 0 0 1 1 3
2.5–5.9 1 2 2 2 3
6–10.9 2 3 3 3 4
11–14.9 3 3 3 4 4
≥15 3 4 4 4 4
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(age and gender), primary tumour site, stage, and extent of
metastatic disease (if present).
Performance status was assessed by the Eastern Coopera-
tive Oncology Group (ECOG) score.12 ECOG PS was assigned
according to patient-reported daily physical function: 0 = fully
active with no restrictions; 1 = restricted in physically strenu-
ous activity but ambulatory and able to carry out light work;
2 = ambulatory and capable of all self-care but unable to carry
out any work activities; 3 = capable of only limited self-care;
and 4 = completely disabled and totally conﬁned to bed or
chair. Patients were followed prospectively until the date of
censoring (11/06/2018) or date of death from any cause (if
present). Survival time was calculated from the date of recruit-
ment to the date of death or censoring, whichever came ﬁrst.
Following written informed consent, patients were pro-
vided instruction on how to complete the QoL questionnaire,
and this was performed during their visit to their treating can-
cer centre or specialist palliative care unit. QoL was recorded
using the European Organization for Research and Treatment
of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 ver-
sion 3.0), which is a 30-item cancer-speciﬁc questionnaire in-
cluding ﬁve functional scales (physical, emotional, cognitive,
social, and role), three symptom scales (fatigue, pain, and
nausea/vomiting), a global health/QoL scale, and six single
items (dyspnoea, insomnia, appetite loss, constipation, diar-
rhoea, and ﬁnancial impact of disease).13 The 28 items mea-
suring functional and symptom scales have a numeric scale:
1 (not at all), 2 (a little), 3 (quite a bit), and 4 (very much).
The two items concerning global QoL have a scale of 1 (very
poor) to 7 (excellent). The raw scores were linearly trans-
formed to give standard scores in the range of 0–100 for each
of the scales and single items as described by the EORTC.13
Higher scores for the functional or global QoL scale represent
a high level of functioning or QoL, whereas higher scores on
the symptom scales represent worse symptomatology. With
regard to EORTC QLQ-C30L, a difference in score of 5–10 was
considered a small clinical difference, a difference in score of
10–20was considered amoderate difference, and a difference
in score ≥20 was considered a large clinically signiﬁcant
difference.14
Statistical analysis
Statistical analysis was completed using SPSS (version 24.0,
SPSS Inc., Chicago, IL, USA). Data are expressed as median
and interquartile range (IQR). Comparisons between groups
of patients were assessed using χ2 test for categorical
variables and unpaired t-tests and Mann–Whitney U-tests
to test for differences in continuous variables depending if
the data were parametric or non-parametric, respectively.
The ﬁrst step in this analysis was to conﬁrm the prognostic
utility of the WLGS in this group of patients before embarking
on the main analysis, which was to assess the relationship
between the WLGS and QoL.
Survival curves were constructed using the Kaplan–Meier
technique, and log-rank test was used to compare survival
between groups of patients. Univariate and multivariate anal-
yses of overall survival (OS) were performed using Cox pro-
portional hazard model. HRs with 95% conﬁdence intervals
(CIs) were calculated. The predeﬁned adjustment variables
in the multivariable models were age, sex, primary disease
site, and ECOG PS. To examine the differences between
BMI-adjusted WLGS and median EORTC QoL functional and
symptom scores, the non-parametric Kruskal–Wallis test
was used, and Jonckheere–Terpstra test was used to test
for a linear trend across BMI-adjusted WLGS. Summary QoL
score, ranging from 0 to 100 (high scores indicating better
QoL), was median dichotomized for multivariate logistic re-
gression analyses in order to assess the impact of the BMI-
adjusted WLGS on overall QoL.15 Patients with a summary
QoL score below the median were given a score of 1, while
those with a score above the median were given a score of
0. Thus, odds ratios (ORs) greater than 1.0 indicate a greater
likelihood of worse QoL. All P-values were two sided, and the
level of signiﬁcance was P < 0.05.
Results
Patient characteristics and demographics
A total of 1027 patients were assessed with characteristics
presented in Table 2. In brief, 51% of patients were male with
Table 2 Demographic and clinical characteristics of patients included in
this study
n % of patients
Sex
Male 524 51
Female 503 49
Age (years)
<65 483 47
65–74 300 29
≥75 244 24
Primary cancer
Gastrointestinal 411 40
Lung 266 26
Other 350 34
Metastatic diseasea
Yes 862 87
No 132 13
Performance status (ECOG)b
0–1 575 59
2 292 30
3 96 10
4 16 1
Percentages given for total available. Other group consists of
breast (n = 91), gynaecological (n = 64), genitourinary (n = 69),
neurological (n = 10), haematological (n = 43), melanoma (n =
40), unknown primary (n= 12), and other (n = 21). ECOG, Eastern
Cooperative Oncology Group.
aAvailable in 994.
bAvailable in 979.
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a median age (IQR) of 66 (57–74) years. Gastrointestinal can-
cers were most prevalent, accounting for 40% of cases,
followed by lung cancer (26%). The majority of patients
(81%) had received chemotherapy in the previous 3 months,
and 59% had a good PS (ECOG 0–1). Distant metastatic dis-
ease was present in 862 (87%) patients, and the most com-
mon sites were liver (35%), lung (25%), or bone (19%).
Patients were a median of 4.6months from diagnosis at point
of data collection (IQR 3.0–13.0 months).
Anthropometric and WL data are presented in Table 3. In
terms of the BMI-adjusted WLGS, 58% of patients had a WL
grade of 0–1, while 12%, 20%, and 10% had WL grades of 2,
3, and 4, respectively. Patients in the ﬁve WL categories did
not differ in relation to sex or age; however, high grade WL
(≥2) was more common in those with gastrointestinal
(45%), lung (46%), gynaecological (48%), and neurological
(56%) cancer compared with breast cancer (26%), genitouri-
nary cancer (23%), and melanoma (31%) (P = 0.002). The
prevalence of patients with high grade WL (grade ≥2) in-
creased with deteriorating ECOG PS [37% (ECOG 0–1), 50%
(ECOG 2), 55% (ECOG 3), 82% (ECOG 4), P < 0.001].
Weight loss grading system and survival
The median OS for the entire cohort was 10.4months (95% CI:
9.4–11.4 months). At the time of censoring, 317 of the 1027
patients (31%) were still alive. Median follow-up time for
these patients was 31.8 months (95% CI: 27.9–35.6). Survival
worsened with increasing WL grades (Figure 1). Median OS
decreased from 16.6 months (95% CI: 13.6–19.6) in WL grade
0 to 5.4months (95% CI: 3.9–6.8) in WL grade 4 (log rank: P<
0.001). On multivariate regression analysis, WL grades 3 and 4
remained independently associated with reduced survival [HR
1.54 (95% CI: 1.22–1.93), P < 0.001 and HR 1.87 (95% CI:
1.42–2.45), P < 0.001, respectively] (Table 4).
Weight loss grading system and quality of life
Quality of life data (EORTC QLQ-C30) were available in 1000
patients. Increasing WL grades were signiﬁcantly associated
with poorer QoL for a number of functional (physical, role,
emotional, cognitive, social, and global health) and symptom
(fatigue, nausea and vomiting, pain, appetite loss, and dys-
pnoea) scales and summary QoL score (Figures 2A–2F and
3A–3G). The greatest difference in median functional QoL
scores between BMI-adjusted WL grades 0 and 4 was ob-
served in role functioning (83 vs. 41.6, P < 0.001) and physi-
cal functioning (80 vs. 60, P < 0.001). The greatest difference
in median QoL symptom scores between BMI-adjusted WL
grades 0 and 4 was observed in appetite loss (0 vs. 33.3, P
< 0.001), pain (0 vs. 33.3, P < 0.001), dyspnoea (0 vs. 33.3,
P < 0.001), insomnia (0 vs. 33.3, P < 0.001), and fatigue
(33.3 vs. 56, P < 0.001), all consistent with a large clinically
meaningful difference (Δ > 20 points). No signiﬁcant differ-
ence in median symptom scores for diarrhoea, constipation,
or ﬁnancial impact score was observed across the BMI-
adjusted WLGS; in fact, for each WL grade, the median score
for diarrhoea, constipation, and ﬁnancial impact was 0. Dete-
riorations in EORTC QLQ-C30 functional and symptom scales
most commonly occurred in BMI-adjusted WL grade ≥2; how-
ever, in some instances, even WL grade 1 was associated with
lower functional (role, emotional, and social function) scores
but not symptom scores. Importantly, increasing WL grades
were associated with deteriorating QoL summary score
across all WL grades (83.2 in WL grade 0 vs. 62.7 in WL grade
4). On multivariate logistic regression, ECOG PS, cancer site,
and BMI-adjusted WL grades were independently associated
with a QoL summary score below the median (<77.7) (Table
5). Although WL grade 1 was not associated with poorer over-
all QoL summary score, compared with WL grade 0, WL grade
2 [OR 1.69 (95% CI: 1.04–2.73), P = 0.034], WL grade 3 [OR
2.06 (95% CI: 1.37–3.11), P = 0.001], and WL grade 4 [OR
4.29 (95% CI: 2.44–7.55), P < 0.001] were independently as-
sociated with an increased risk of having a QoL summary
score below the median.
Discussion
Our ﬁndings highlight that the WLGS is capable of identifying
patients at risk of poorer QoL. In particular, WL grade 4 is as-
sociated with a particularly poor prognosis and increased
symptom burden.
Table 3 Anthropometric and nutritional status characteristics of patients
included in this study
Characteristic Total n = 1027
BMI (kg/m2)a, n (%)
Underweight (<18.5 kg/m2) 68 (7)
Healthy weight (18.5–24.9 kg/m2) 402 (42)
Overweight (25–29.9 kg/m2) 299 (32)
Obese (≥30 kg/m2) 180 (19)
Weight loss (>2%)b, n (%) 399 (42)
Median weight loss (IQR) (%) 7.3 (4.4 to 12.6)
Weight stable (±2%), n (%) 449 (47)
Weight gain (>2%), n (%) 103 (11)
Median weight gain (IQR) (%) +4.7 (+3.2 to +8.1)
BMI-adjusted WLGSc, n (%)
0 334 (35)
1 214 (23)
2 112 (12)
3 186 (20)
4 97 (10)
Percentages given for total available. BMI, body mass index; BMI-
adjusted WLGS, body mass index-adjusted weight loss grading sys-
tem; IQR, interquartile range.
aAvailable in 949.
bAvailable in 951.
cAvailable in 943.
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Figure 1 Kaplan–Meier curve displaying cumulative survival by weight loss grade. Censored cases indicated by +.
Table 4 Estimated crude and adjusted hazard ratios for Cox proportional hazard model assessing the effect of variables associated with survival
n
Univariate analysis Multivariate analysisa
HR (95% CI) P-value HR (95% CI) P-value
Sex
Men 524 1.00 1.00
Women 503 0.88 (0.76–1.02) 0.092 0.94 (0.79–1.10) 0.428
Age (years)
<65 483 1.00 1.00
64–74 300 1.10 (0.93–1.31) 0.276 1.02 (0.85–1.23) 0.854
≥75 244 1.21 (1.00–1.46) 0.048 0.93 (0.79–1.10) 0.481
Cancer site
Gastrointestinal 411 1.00 1.00
Lung 266 1.36 (1.14–1.64) 0.001 1.26 (1.03–1.54) 0.024
Other 350 0.64 (0.54–0.77) <0.001 0.68 (0.56–0.83) <0.001
ECOG
0–1 575 1.00 1.00
2 292 2.01 (1.69–2.39) <0.001 1.84 (1.53–2.21) <0.001
3 96 3.83 (3.00–4.89) <0.001 3.31 (2.37–4.14) <0.001
4 16 22.69 (13.47–38.25) <0.001 15.45 (8.20–29.11) <0.001
BMI-adjusted WLGS
Grade 0 312 1.00 1.00
Grade 1 201 1.31 (1.07–1.62) 0.010 1.16 (0.93–1.44) 0.189
Grade 2 107 1.44 (1.11–1.86) 0.006 1.27 (0.97–1.65) 0.084
Grade 3 182 1.71 (1.37–2.13) <0.001 1.54 (1.22–1.93) <0.001
Grade 4 97 2.28 (1.75–2.97) <0.001 1.87 (1.42–2.45) <0.001
Cases available for analysis: n = 899. BMI-adjusted WLGS, body mass index-adjusted weight loss grading system; CI, conﬁdence interval;
ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio.
aMultivariate model adjusted for sex, age, cancer site, and ECOG PS.
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We report signiﬁcant deteriorations in both EORTC QLQ-
C30 functional and symptom scores with increasing WL
grades. In terms of symptom burden, appetite loss, pain,
dyspnoea, insomnia, and fatigue increased by a median
score of >20 points between WL grade 0 and WL grade
4, which is considered to be a large clinically signiﬁcant dif-
ference. Similar results were observed in physical and role
functioning scores across WL grades 0–4 (Δ > 20 points),
whereas cognitive, social, and emotional functioning deteri-
orated by between 10 and 20 points, indicating a moderate
clinical difference. Importantly, the overall QoL summary
score decreased across WL grades from 83.2 in WL grade
0 to 62.7 in WL grade 4 (P < 0.001), and on multivariate
analysis, higher grades of WL were independently associ-
ated with poorer overall summary QoL compared with WL
grade 0. Our ﬁndings reﬂect those reported by Vagnildhaug
and colleagues, whereby all cachexia domains (dietary in-
take, performance score, appetite, and fatigue) signiﬁcantly
decreased with increasing WL grades.8
The WLGS was the ﬁrst step towards data-driven ap-
proaches for the development of robust diagnostic criteria
for cancer cachexia that relate optimally to meaningful
patient-centred outcomes (e.g. survival). However, whether
the WLGS alone is sufﬁcient to identify cancer cachexia or its
stages is unknown. Blum et al. reported that WL and BMI
can distinguish between cachectic and non-cachectic patients,
but neither WL nor BMI is sufﬁcient to classify patients into
more than two stages of cachexia.16 Cachexia represents a
spectrum of conditions and can range in severity and clinical
presentation from pre-cachexia, identiﬁed by early clinical
and metabolic signs, to refractory cachexia, where extensive
muscle and fat depletion is evident, and patients are often
immune-compromised.1 Recognition of these stages of ca-
chexia is important as these stages have different implications
in the anabolic therapy response. Vagnildhaug et al.8 reported
that theWLGS was predictive of the likelihood of cachexia pro-
gression, such that progression to more severe WL grades was
greater in patients with WL grade 2 (39%) compared with WL
grades 0 (19%) and 1 (22%). Supporting this observation was
that patients with WL grade 2, similar to our ﬁndings, had a
higher cachexia-related symptom load and poorer physical
function compared with lower WL grades; thus, the authors
suggested that WL grade 2 was ﬁtting with the ‘pre-cachexia’
phase. Identiﬁcation of the pre-cachexia stage is of great clin-
ical importance as this is the stage in which cachexia treatment
should be initiated to achieve maximal response. Although the
relationship between the WLGS and stages of cachexia5 is not
established and is outside the remit of the present study, it
would be reasonable to assume that patients with WL grade
4 have refractory cachexia. This is the phase in which patients
experience depletion of fat reserves, severe muscle wasting,
and immunosuppression, and nutritional treatment initiated
Figure 2 Relationship between body mass index (BMI)-adjusted weight loss grades (0–4) and median (interquartile range) functional scores from qual-
ity of life [European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-30)] assessed by the Kruskal–Wallis
test.
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in this phase often fails to show clinical beneﬁts.5 In the
present ﬁndings, supporting this observation, WL grade 4
was associated with signiﬁcantly shorter survival [HR 1.87
(95% CI: 1.42–2.45), P< 0.001] and reduced QoL in numerous
functional and symptom domains.
In addition to the ability of the WLGS in detecting poor
prognosis and QoL, it remains to be determined if the WLGS
is capable of identifying patients at risk of treatment and
post-operative complications who may beneﬁt from pre-
treatment rehabilitation. Recently, the WLGS was identiﬁed
as an independent risk factor for post-operative complica-
tions in a cohort of 84 patients undergoing colorectal cancer
resection. Patients with a WL grade ≥3 were at almost double
the risk of experiencing a grade II or higher complication post-
surgery [risk ratio (RR) 1.90 (95% CI: 1.22–3.39), P = 0.048].17
Patients identiﬁed with high grade WL who are at risk of
poorer QoL may beneﬁt from nutritional support aimed at at-
tenuating WL. Nutritional support can be provided orally
through dietary counselling ideally by a registered dietitian, in-
corporating energy and protein-dense diets, food fortiﬁcation,
and oral nutritional supplements or a combination of all
three.4 Importantly, nutritional interventions have proven
successful in improving some aspects of QoL in patients with
cancer. In a recent systematic review and meta-analysis exam-
ining oral nutritional interventions in malnourished patients
with cancer, Baldwin et al. reported signiﬁcantly greater ben-
eﬁts to emotional functioning, dyspnoea, loss of appetite, and
global QoL in patients receiving oral nutritional interventions
compared with routine care. Importantly, the improvements
in QoL were consistent with both small and large differences
Figure 3 Relationship between body mass index (BMI)-adjusted weight loss grades and median (interquartile range) symptom scores from quality of
life (QoL) domains [European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-30)] assessed by the
Kruskal–Wallis test.
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in scores and likely to be clinically meaningful.18,19 ESPEN
guidelines on nutrition support in oncology now outline Grade
A evidence to support the use of intensive dietary advice with
or without the use of oral nutritional supplements to increase
dietary intakes and prevent WL during radiotherapy and che-
motherapy.7 Nutritional support may be best suited towards
patients with WL grade 1 or 2, which also have impaired
QoL, whereas patients with high gradeWL (e.g. 3 or 4) and ad-
vanced disease may beneﬁt from early referral to palliative
care services, irrespective of formal assessment of symptom
burden, as the ﬁndings from the present study demonstrate
that these patients have markedly impaired QoL and survival.
Our study is associated with a number of strengths and lim-
itations. Although our cohort is composed of a relatively large
sample of patients with incurable disease, the tumour group is
heterogeneous. Our data were limited in that patients typi-
cally had a good PS and were early in their disease trajectory;
therefore, these ﬁndings may not be representative of the en-
tire population. In addition, our ﬁndings cannot be extrapo-
lated to other populations (e.g. cancer survivors), and
therefore, further research is required to validate these ﬁnd-
ings in external cohorts of patients. It is also challenging to dis-
entangle if differences in QoL across WL categories simply
reﬂect more advanced disease, increased disease burden,
and resultant increased symptom burden or are directly re-
lated to WL. Further, the ﬁndings of the present study do
not assess whether the WLGS is superior to other measures
associated with reduced survival such as ECOG PS, the latter
having a clear relationship with QoL and widely used clinically.
However, the present ﬁndings suggest that WL grades were
associated with poorer QoL scores independent of ECOG PS,
highlighting that both have an impact on summary QoL score.
Future work that examines these in combination would be of
interest. Data on WL prior to 3 months were not available for
the cohort described herein. This may have been interesting
to ascertain the recent degree of WL compared with overall
WL. Importantly, longitudinal measures of body composition
were not examined in this analysis, and therefore, the compo-
sition of weight lost was unknown (skeletal muscle vs. adipose
tissue). Given the convenience recruitment strategy, patients
may have been at different time points of their disease trajec-
tory when QoL was assessed, which may have inﬂuenced QoL
scores. In addition, we did not document if patients received
oral nutritional supplements and enteral or parenteral nutri-
tion or if they were prescribed any medications that might in-
ﬂuence appetite and weight gain.
We report that the WLGS may be useful in identifying pa-
tients at risk of poor QoL. WL grade 4 is independently asso-
ciated with a particularly poor prognosis and increased
symptom burden, and identiﬁcation of patients with WL
grade 4 could be useful in identifying those who may beneﬁt
from early referral to palliative care services.
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